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Problems with vascular access are an important cause of
morbidity and mortality in hemodialysis patients. We
established a rodent model of arteriovenous fistula by
anastomosing the end of a lateral vein to the side of the
ventral artery of the rat tail. All operations were technically
successful and in all animals the fistula was patent with a
dilated fistula vein clearly visible after 28 days. Neointimal
hyperplasia was found in 4 out of 5 fistulae with varied
pathology from immature to more mature lesions seen both
proximal and distal to the anastomosis. There was no
particular pattern to the presence of or type of lesion found
at any particular site of the fistulae. This fistula promises to
be useful in analyzing pathologic processes that occur in
native arteriovenous fistulae since the vein is accessible to
functional studies and to test new subcutaneous or
intravascular treatments.
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To perform hemodialysis, reliable vascular access is required.
It is universally agreed that the optimal form of access is a
native arteriovenous fistula (AVF). Although these are
superior to synthetic arteriovenous grafts, they have a limited
patency largely due to stenosis caused by neointimal
hyperplasia.1 Problems with vascular access are an important
cause of morbidity and mortality in hemodialysis patients. In
the United States, it has been estimated that $1 billion dollars
per year are spent on vascular access and its complications.2
It is important that measures to prolong the life of vascular
access are explored to decrease morbidity and mortality in
dialysis patients, and to decrease the resulting economic costs
to the health service. The cause of early primary failure of
AVFs appears to be neointimal hyperplasia.3 At present there
are no medical therapies that have been shown to be
beneficial for the preservation of vascular access.
To understand the processes leading to AVF stenosis and
to develop effective treatments, animal models are necessary.
AVFs have been formed in rodents between aorta and vena
cava,4,5 carotid and jugular veins,6 and femoral vessels.7 In
none of these models is the fistula vein superficial and visible.
Our aim was to produce an animal model of the pathology
that occurs in a native AVF using a superficial fistula vein that
would be accessible to inspection and that would be available
for studies of local therapies. The vessels in the rat tail include
a lateral vein and a artery on each side, and a ventral artery
with two adjacent veins. We found that the ventral artery was
the only one that was large enough to be used. The ventral
veins were large enough to be used, and it would have been
technically easier to use these in a side-to-side anastomosis.
However, as our aim was to create a fistula in which the vein
was superficial, we transposed the lateral vein.
Fistula formation was performed by a surgeon experienced
in microvascular techniques using an Olympus SZX9
operating microscope. All animal procedures were performed
in accordance with UK Home Office and local regulations.
Adult male Lewis rats (Harlan, UK) were anesthetized, the
lateral tail vein was mobilized, and blood flow was tempo-
rarily stopped using a suture (coarse upper suture, Figure 1a).
The distal end was tied off (4-0 suture, Ethicon, West
Lothian, UK), cut, and transposed. The ventral artery was
exposed and clamped (Figure 1b). The end of the transposed
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vein was then anastomosed to the side of the artery using
a 10-0 surgical suture with needle (Bear, Chiba, Japan)
(Figure 1c). The coarse suture stopping blood flow in the
fistula vein was then removed. In total, five operations were
performed as described, and all operations were immediately
technically successful. At 28 days, fistula patency was assessed
by dissection under anesthesia and in all five cases the fistula
was patent. A length of fistula vein approximately 1.5 cm in
length was taken. This was divided into three sections, which
were labeled to denote their proximity to the anastomosis.
Figure 2 shows one such fistula after dissection under
anesthesia. The dilated fistula vein comes across from the
lateral side of the tail to an anastomosis with the ventral
artery.
We then examined fistula veins for pathological changes.
The fistula vein was fixed in 10% formalin and embedded in
wax. For each fistula formed, there were three samples (each
approximately 0.5 cm in length) that were differing distances
from the anastomosis. Multiple sections taken at different
levels from each sample were examined for pathological
changes. Sections were stained with periodic acid Schiff
reagent (PAS) or elastic Van Geisin (EVG) stain. For macro-
phage staining, sections were microwaved in 0.1 M citrate (pH
6) for 10 min, and stained for CD68 with clone ED1 (Serotec,
Oxford, UK). Detection was with biotinylated sheep anti-
mouse IgG followed by horseradish peroxidase avidin–biotin
complexes (Vector Laboratories, Peterborough, UK) and
3,30-diaminobenzidine substrate. For smooth muscle actin
staining, the primary antibody was clone 1A4 (Sigma, Poole,
UK) detected with the Envision polymer system (Dako,
Ely, UK).
Pathological changes were seen in the neointima in four
out of five fistulae. It is possible that lesions were missed in
this one fistula due to the histological sampling method used.
These varied from cellular immature lesions to more mature
lesions. These changes were seen both near to and away from
the anastomosis, with no particular pattern as to the presence
or type of lesion seen at a particular site in the fistula. It
should be noted, however, that in all four fistulae, lesions
were seen near the anastomosis. This provides a good parallel
to the clinical situation, where stenosis often develop near
the anastomosis, but may occur at any distance from the
anastomosis. Further work will be required to clarify the
factors leading to lesions at particular sites in our model.
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Figure 1 | Formation of arteriovenous fistulae. (a) A lateral incision was made and the lateral tail vein was mobilized. A fine suture is
shown by the arrow. This was used to tie off the vein before cutting it and transposition. The large suture was used to prevent blood
flow through the vein during surgery and was released after the anastomosis was made. (b) Through a ventral incision, the ventral
artery was located in its sheath and mobilized before clamping. (c) After transposing the cut lateral tail vein to bring the end to the side
of the ventral artery, the anastomosis was made. Arrows indicate the vein and the artery above the anastomosis.
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Figure 2 | Appearance of fistula vein. After 28 days, the dilated
fistula vein was clearly visible through the skin of the tail,
and is shown here after dissection under anesthesia. The vein
and the artery are indicated by arrows.
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Table 1 summarizes the changes seen in the five fistulae.
Smooth muscle actin-positive cells were found in both the
mature neointimal lesions and the immature cellular lesions.
Figure 3 shows representative sections of mature and
immature lesions, with periodic acid Schiff-, elastic Van
Geisin-, and smooth muscle actin-stained sections. Sections
were examined for the presence of macrophages using anti-
CD68 staining, and we could not detect macrophages in
either cellular or mature lesions.
The use of a peripheral superficial vein in our model is a
major advantage compared with previously described studies.
In both rats and mice, AVFs have been formed between the
aorta and the vena cava and used as a model of cardiac
failure.4,5 Recently, the changes in vein architecture have been
described in this system as a model of hemodialysis AVF
pathology.8 The findings in this model may be complicated
by the presence of cardiac failure, and processes in central
vessels may be different from more peripheral ones. In
addition, the fistula vein is not accessible due to the central
location. More recently an AVF between large vessels was
described in the mouse. In this model, the end of the
common carotid artery was anastomosed to the side of the
internal jugular vein.6 In this model, neointimal hyperplasia
was found in the artery at the anastomosis, and in the vein
only directly opposite the anastomosis. The pathology in the
vein in this model appears to be a direct result of injury from
the arterial blood inflow, and this type of fistula, in which the
end of an artery is joined to the side of a vein, is not used
clinically. In addition, the fistula vein in this model is not
superficial. Macrophages were seen in early arterial neointi-
mal lesions, but their presence or absence in the venous
neointimal lesions was not reported. It is therefore difficult to
know if our model of venous neointimal hyperplasia differs
in this respect. AVFs have also been described in rats between
the femoral artery and the vein.7 Massive fibrosis of the
media and fusion with the adventitia were found histologi-
cally, and all animals developed ipsilateral hindlimb edema.
This suggests that this would not give a good model of
dialysis access dysfunction. In addition, the fistula vein is not
superficial in this model either. In humans, upper limb veins
contain valves that may contribute to fistula stenosis. We did
not find valves in the rat tail veins, but did not specifically
search for these. This potential structural difference may need
to be considered when using our model.
In conclusion, we have established a model of an AVF in a
peripheral superficial vein, in which neointimal hyperplasia
develops after 28 days. We were limited to 28 days by our
project license, but it seems likely that more severe pathology
will develop after a longer time period. This model may be
used to investigate the factors leading to AVF pathology, and
also to assess therapeutic interventions. Our model will be
particularly valuable for investigating local subcutaneous or
intravascular therapies due to the superficial nature of the
vein.
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Table 1 | Summary table of histological findings after 28 days
Fistula
number
Proximal to
anastomosis Middle
Distal to
anastomosis
1 Mature None None
2 Early None None
3 Early Early Early
4 Intermediate Mature and early Early
5 None None None
All five fistulae were assessed and the presence of histological lesions documented
in 0.5 cm lengths of fistula vein that were different distances from the anastomosis.
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Figure 3 | Representative histology is shown. A mature
neointimal lesion is shown in a PAS-stained section, indicated by
an arrowhead (a), and an EVG-stained section (b) to show the
internal elastic lamina. This is indicated by an arrow, with the
neointimal lesion indicated by an arrowhead. (c) Smooth muscle
actin-positive cells were found in the mature neointimal lesions.
(d, e, and f) PAS-, EVG-, and smooth muscle actin-stained sections
for an immature cellular lesion. Arrowheads indicate the
neointimal lesion in panels d and e, and the internal elastic lamina
is indicated by an arrow in panel e.
530 Kidney International (2008) 74, 528–531
t e c h n i c a l n o t e s T Lin et al.: Arteriovenous fistula in the rat tail
3. Roy-Chaudhury P, Arend L, Zhang J et al. Neointimal hyperplasia in early
arteriovenous fistula failure. Am J Kidney Dis 2007; 50: 782–790.
4. Chancey AL, Brower GL, Peterson JT et al. Effects of matrix
metalloproteinase inhibition on ventricular remodeling due to volume
overload. Circulation 2002; 105: 1983–1988.
5. Perry GJ, Mori T, Wei CC et al. Genetic variation in angiotensin-converting
enzyme does not prevent development of cardiac hypertrophy or
upregulation of angiotensin II in response to aortocaval fistula. Circulation
2001; 103: 1012–1016.
6. Castier Y, Lehoux S, Hu Y et al. Characterization of neointima lesions
associated with arteriovenous fistulas in a mouse model. Kidney Int 2006;
70: 315–320.
7. Pascarella L, Schmid-Schonbein GW, Bergan J. An animal model of venous
hypertension: the role of inflammation in venous valve failure. J Vasc Surg
2005; 41: 303–311.
8. Nath KA, Kanakiriya SK, Grande JP et al. Increased venous
proinflammatory gene expression and intimal hyperplasia in an
aorto-caval fistula model in the rat. Am J Pathol 2003; 162: 2079–2090.
Kidney International (2008) 74, 528–531 531
T Lin et al.: Arteriovenous fistula in the rat tail t e c h n i c a l n o t e s
